Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)
Analysts hound Biogen with questions over Aduhelm's $56K price point as news of Alzheimer's OK ripples through global markets
It’s been nearly 24 hours since the FDA handed down its controversial decision to approve Biogen’s Aduhelm drug for Alzheimer’s disease, and reactions from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
